<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04812522</url>
  </required_header>
  <id_info>
    <org_study_id>Clean-CS</org_study_id>
    <nct_id>NCT04812522</nct_id>
  </id_info>
  <brief_title>Clean-CS: A Program to Improve the Safety of C-section</brief_title>
  <acronym>Clean-CS</acronym>
  <official_title>CheckList Expansion for Antisepsis and iNfection Control in Cesarean Section - CLEAN-CS: A Cluster-Randomized, Stepped Wedge Interventional Trial to Reduce Postoperative Infections Following Cesarean Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Lifebox Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ethiopian Society of Obstetricians and Gynecologists</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Lifebox Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Executive summary: Cesarean delivery, or section (CS), is the single most common surgical&#xD;
      procedure performed. Estimates indicate that in low resource settings, CS comprises up to 50%&#xD;
      of more of the total volume of operations performed. The World Health Organization recommends&#xD;
      national CS rates of between 10-15% to save lives and improve maternal and neonatal outcomes.&#xD;
      Population-based work indicates that CS rates of up to 19% are demonstrably related to&#xD;
      improved maternal and neonatal survival. However, complications are common, and gynecological&#xD;
      and obstetric surgical interventions are associated with high rates of morbidity. In low&#xD;
      resource settings, complication rates are particularly high.&#xD;
&#xD;
      The intervention being tested is based on a previously developed program called Clean Cut.&#xD;
      Clean Cut is an adaptive, multimodal surgical infection prevention program that integrates&#xD;
      perioperative process improvement and patient outcomes measurement using process mapping,&#xD;
      training and improved management practices, and compliance with critical standards of&#xD;
      surgical antisepsis. It was successfully piloted in five surgical departments in Ethiopia,&#xD;
      and reduced the relative risk of infection by 35%. This has been adapted specifically for&#xD;
      obstetric and gynecological operations and will be evaluated in a cluster randomized stepped&#xD;
      wedge trial design in ten maternity hospitals/departments in Ethiopia in order to reduce&#xD;
      infections and other complications for women undergoing cesarean delivery and other obstetric&#xD;
      and gynecologic operations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Cesarean section (CS) is the single most common surgical procedure performed&#xD;
      worldwide. In Ethiopia, estimates suggest that CS accounts for 30-50% of all operations&#xD;
      performed. Population-based work indicates that CS rates of up to 19% are demonstrably&#xD;
      related to improved maternal and neonatal survival. In Ethiopia, the national CS rate per&#xD;
      live births was 1.9% in 2016, but rates are highly variable by region. In addition,&#xD;
      complications are common, and gynecological and obstetric surgical interventions are&#xD;
      associated with high rates of morbidity. Infections and complications following CS are&#xD;
      estimated to cause 15% of maternal deaths in the country, and the overall SSI rate following&#xD;
      CS is estimated at 9%. Failure to administer preoperative antibiotics has been highlighted as&#xD;
      a particular improvement opportunity, and is one of the critical processes this program will&#xD;
      focus on.&#xD;
&#xD;
      Lifebox, a charity devoted to improving surgical and anesthesia safety, developed a program&#xD;
      to improve compliance with the WHO Surgical Safety Checklist and improve adherence to&#xD;
      critical standards of perioperative infection prevention. This initiative, called Clean Cut,&#xD;
      is an adaptive, multimodal surgical infection prevention program that integrates&#xD;
      perioperative process improvement and patient outcomes measurement using process mapping,&#xD;
      training and improved management practices, and compliance with critical standards of&#xD;
      surgical antisepsis. The program was the result of a joint collaboration between the&#xD;
      Ethiopian Federal Ministry of Health (FMOH), the Surgical Society of Ethiopia, and Lifebox&#xD;
      and resulted in a 35% relative risk reduction in postoperative infections.&#xD;
&#xD;
      Aims -&#xD;
&#xD;
      Primary:&#xD;
&#xD;
        1. To reduce postoperative infections in patients undergoing CS Secondary&#xD;
&#xD;
        2. To reduce postoperative infections in patients undergoing other obstetrical and&#xD;
           gynecological operations&#xD;
&#xD;
        3. To improve compliance with a core set of critical perioperative infection prevention and&#xD;
           control practices that are essential to reducing infectious risks from surgical&#xD;
           intervention&#xD;
&#xD;
        4. To reduce the need for reoperation in patients undergoing obstetrical and gynecological&#xD;
           operations&#xD;
&#xD;
        5. To reduce the length of stay due to infectious and other complications for patients&#xD;
           undergoing obstetrical and gynecological operations&#xD;
&#xD;
        6. To reduce mortality rates in mothers undergoing CS&#xD;
&#xD;
        7. To reduce mortality rates in women undergoing obstetrical and gynecological operations&#xD;
&#xD;
        8. To reduce mortality rates in neonates delivered by CS Ancillary&#xD;
&#xD;
        9. To assess facility readiness for and capacities to engage in quality improvement&#xD;
           programs in surgery&#xD;
&#xD;
      The Intervention: Clean Cut focuses on improving compliance with six critical perioperative&#xD;
      infection prevention standards:&#xD;
&#xD;
        -  appropriate skin preparation of the surgeon's hands and the surgical site&#xD;
&#xD;
        -  maintenance of the sterile field by ensuring the integrity and sterility of surgical&#xD;
           gowns, drapes, and gloves&#xD;
&#xD;
        -  confirmation of instrument sterility&#xD;
&#xD;
        -  appropriate antibiotic administration&#xD;
&#xD;
        -  complete swab counts&#xD;
&#xD;
        -  routine use of the WHO Surgical Safety Checklist&#xD;
&#xD;
      Clean Cut is implemented in five phases:&#xD;
&#xD;
        1. Identification of a Clean Cut team to include members from all perioperative&#xD;
           disciplines: Ob/Gyn, surgery, nursing, anesthesia, QI personnel and operating room (OR)&#xD;
           management;&#xD;
&#xD;
        2. Establishment of a baseline by conducting context assessments and process mapping the&#xD;
           six perioperative standards, and establishing a data collection system;&#xD;
&#xD;
        3. Modification and implementation of the WHO Surgical Safety Checklist to fit local&#xD;
           practices;&#xD;
&#xD;
        4. Ongoing data feedback to connect baseline data with process maps, coupled with&#xD;
           site-specific action plans for improvement;&#xD;
&#xD;
        5. Targeted training, workshops, and refresher courses using local providers, coupled with&#xD;
           a transition to hospital management for sustaining the program.&#xD;
&#xD;
      Clean Cut has been adapted specifically for obstetric and gynecological operations and will&#xD;
      implement it in ten maternity hospitals/departments in Ethiopia in order to reduce infections&#xD;
      and other complications for women undergoing cesarean delivery and other obstetric and&#xD;
      gynecologic operations. Clean Cut has been designed with sustainability at its core - the&#xD;
      strategy emphasizes teamwork and collective leadership to identify and address critical gaps&#xD;
      in perioperative safety processes.&#xD;
&#xD;
      Study Design: The impact of the CS-tailored Clean Cut program will be tested through a&#xD;
      cluster randomized stepped-wedge study design at 10 hospitals over the course of 24 months.&#xD;
      Each selected hospital will be distributed into two groups based on the type of facility:&#xD;
      university teaching and referral hospitals in one group, and regional, district, and&#xD;
      community hospitals in another. Five clusters and their order will be randomly established,&#xD;
      paring a teaching/referral hospital with a regional/district/community hospital. These&#xD;
      hospitals will start by collecting inpatient and outpatient outcomes on all patients&#xD;
      undergoing CS prior to implementation. Over the course of 10 months, 2 hospitals at a time&#xD;
      will begin implementing Clean Cut at 2-month intervals. Each starts by assembling a&#xD;
      multidisciplinary improvement team, undergoing team training on WHO Surgical Safety Checklist&#xD;
      use and implementation, and gathering compliance information about intraoperative safety&#xD;
      practices. The initiation of Clean Cut will also involve creating facility-specific process&#xD;
      maps of each critical perioperative practice. Once these process maps and compliance data are&#xD;
      complete, usually after 2-4 weeks, the team establishes an adaptive, facility-driven&#xD;
      improvement plan based on process gaps and barriers to best practice.&#xD;
&#xD;
      Study sites and facility eligibility: Study sites will consist of ten hospitals in Ethiopia&#xD;
      that provide maternal surgical services. Five of these hospitals will be university teaching&#xD;
      or referral hospitals (aka specialized or referral hospitals), and five will be regional,&#xD;
      district or smaller community hospitals (aka general or regional hospitals).&#xD;
&#xD;
      Site randomization: Each selected hospital will be distributed into two groups based on the&#xD;
      type of facility: university teaching and referral hospitals in one group, and regional,&#xD;
      district, and community hospitals in another. One hospital in each group will be paired to&#xD;
      create five clusters; these pairings will be purposive as district and referral hospitals in&#xD;
      Ethiopia typically have long-standing relationships which will facilitate implementation at&#xD;
      the cluster level and prevent inadvertent crossover of the intervention prior to&#xD;
      randomization. The sequence of implementation for each of the five clusters will be&#xD;
      established using computer-based randomization (https://www.randomizer.org/).&#xD;
&#xD;
      Participants: As obstetric and gynecologic operations are typically undertaken in separate,&#xD;
      dedicated operating theatres, we will focus our prospective observations on patients admitted&#xD;
      to these theatres. Any patient undergoing surgery at any time in one of the targeted&#xD;
      operating theatres is eligible for inclusion; there will be no exclusion criteria. Enrollment&#xD;
      will occur at the time of observation and will include various times (day and night) and days&#xD;
      of the week (weekdays and weekends). As the standards being implemented are not in dispute&#xD;
      and are considered critical for ensuring antisepsis and sterility, patient informed consent&#xD;
      will not be obtained. While our focus will be on cesarean delivery, any obstetric or&#xD;
      gynecological operation will be included, with the inclusion of other operations in this&#xD;
      populations (such as appendectomy for appendicitis that is found incidentally or misdiagnosed&#xD;
      as ovarian torsion, for example). There will be no age range limit.&#xD;
&#xD;
      We will also interview key hospital personnel to understand the context of each facility, its&#xD;
      experience with quality improvement initiatives, and the perceived importance of this work to&#xD;
      patient safety, patient care, and the work routine. These interviewees will be recruited from&#xD;
      the implementation teams involved in Clean Cut. We will also administer surveys in&#xD;
      conjunction with Ariadne Labs, a partner in this work, to understand the context,&#xD;
      perceptions, and priorities of the various institutions, and how the Clean-CS team can&#xD;
      support implementation at the time of intervention (phases 3, 4, and 5)&#xD;
&#xD;
      Sample size and power calculations: Our prior work and review of the literature indicate a&#xD;
      baseline SSI incidence of 12% following CS. Given our past work has reduced SSI by 35%, we&#xD;
      assume an effect size of Clean Cut resulting in a 25% absolute reduction in SSI (from 12% to&#xD;
      9%). We expect that the preintervention sample will match the postintervention sample in size&#xD;
      and general demographic characteristics. As we do not have specific information on the&#xD;
      interhospital characteristics or outcomes, we assume an intracluster correlation (ICC) of 0.1&#xD;
      With recruitment of 80-90 patients per cluster per month over 18 months, we expect the final&#xD;
      sample to include 7,200 to 8,100 patients, which will be sufficient to detect our expected&#xD;
      difference within a reasonable range of ICCs.&#xD;
&#xD;
      Details of our power calculations, data handling, and data forms will be available in our&#xD;
      online protocol: https://www.lifebox.org/cleancs/&#xD;
&#xD;
      Analysis: We will conduct pre/post analyses with our planned assessment controlling for risk&#xD;
      factors and other demographic and procedure variables listed below that are known to affect&#xD;
      infection rates. We will compare patient demographics pre and post intervention as well to&#xD;
      evaluate overall matching of patients in each part of the study. We will evaluate compliance&#xD;
      individually and in an all-or-none manner as previously described in our Clean Cut pilot&#xD;
      work. We will undertake a planned subanalysis of patients observed early during baseline&#xD;
      (first two months) and compare them to patients undergoing surgery during the final stage of&#xD;
      the study (last two months) after implementation of the program has had time to take effect&#xD;
      to assess primary and secondary outcomes.&#xD;
&#xD;
      We will not conduct any interim analyses as we believe that neither benefit nor futility&#xD;
      would be readily observable at an interim analysis given the implementation strategy and&#xD;
      approach; furthermore, even if we were able to assess benefit or futility we would want to&#xD;
      continue the trial to fully study the mechanisms of implementation. Regarding an assessment&#xD;
      of harm, if such an outcome were noted we believe this would most likely be due to detection&#xD;
      bias with improving ability to capture complications as the study progressed, and we would&#xD;
      want to let the study play out to mitigate this detection bias over time.&#xD;
&#xD;
      Risks, benefits, and IRB review: The protocol was approved by the Armauer Hansen Research&#xD;
      Institute (AHRI/ ALERT) Ethics Review Committee and the Ministry of Science and Higher&#xD;
      Education. As the standards being implemented are not in dispute and are considered critical&#xD;
      for ensuring antisepsis and sterility, patient informed consent will not be obtained and&#xD;
      waiver for informed consent has been requested. The Investigator will ensure that this trial&#xD;
      is conducted in accordance with relevant regulations and with Good Clinical Practice.&#xD;
&#xD;
      The benefits of this study are improvements in compliance with best practices in&#xD;
      perioperative infection prevention. There are no known risks other than those typically&#xD;
      associated with surgery that are not specific to this trial.&#xD;
&#xD;
      Institutional oversight: Lifebox and the Ethiopian Society of Obstetricians and Gynecologists&#xD;
      are jointly organizing and running this study. Lifebox will be responsible for data security&#xD;
      and analysis. The ten hospitals are listed in this protocol.&#xD;
&#xD;
      Funding: UBS Optimus Foundation through a Gates Grand Challenge Grant&#xD;
&#xD;
      Study Contact:&#xD;
&#xD;
      Thomas Weiser MD MPH Associate Professor of Surgery, Stanford University Consulting Medical&#xD;
      Officer, Lifebox&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>cluster randomized stepped wedge design</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Surgical infections following cesarean delivery</measure>
    <time_frame>18 months</time_frame>
    <description>Number of patients undergoing cesarean delivery diagnosed with postoperative infection in hospital or up to 30 days post surgery; measured by change pre and post intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgical infections following obstetric and gynecologic operations</measure>
    <time_frame>18 months</time_frame>
    <description>Number of patients undergoing obstetric and gynecologic operations diagnosed with postoperative infection in hospital or up to 30 days post surgery; measured by change pre and post intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance with infection prevention practices</measure>
    <time_frame>18 months</time_frame>
    <description>Number of patients undergoing obstetric and gynecologic surgery receiving each of the six perioperative infection prevention and control practices defined by the Clean Cut program; measured by change pre and post intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reoperation following obstetric and gynecologic surgery</measure>
    <time_frame>18 months</time_frame>
    <description>Number of patients requiring reoperation or return to the operating theatre prior to discharge following obstetric and gynecologic surgery; measured by change pre and post intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>18 months</time_frame>
    <description>Mean and median length of stay, in days, following following obstetric and gynecologic surgery; measured by change pre- and post-intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative maternal mortality</measure>
    <time_frame>18 months</time_frame>
    <description>Number of mothers who die in hospital or up to 30 days following CS; measured by change pre- and post-intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative mortality</measure>
    <time_frame>18 months</time_frame>
    <description>Number of women who die in hospital or up to 30 days following obstetric and gynecologic surgery; measured by change pre and post intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal mortality</measure>
    <time_frame>18 months</time_frame>
    <description>Number of newborn/fetal deaths prior to discharge of mother following cesarean delivery; measured by change pre and post intervention</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Atlas/MKA Facility Readiness Toolkit score</measure>
    <time_frame>24 months</time_frame>
    <description>Comparison of facility characteristics including assessments of Commitment and Motivation, Ability to Implement, Internal Culture, Clinical Team Functionality, and Knowledge and Ability to engage in quality improvement programs in surgery as measured by the Atlas/MKA Facility Readiness Toolkit</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">6000</enrollment>
  <condition>Cesarean Section Complications</condition>
  <arm_group>
    <arm_group_label>Clean Cut intervention - Cluster 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cluster 1 will receive the Clean Cut infection prevention intervention at random time point &quot;A&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clean Cut intervention - Cluster 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cluster 2 will receive the Clean Cut infection prevention intervention at random time point &quot;B&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clean Cut intervention - Cluster 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cluster 3 will receive the Clean Cut infection prevention intervention at random time point &quot;C&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clean Cut intervention - Cluster 4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cluster 4 will receive the Clean Cut infection prevention intervention at random time point &quot;D&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clean Cut intervention - Cluster 5</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cluster 5 will receive the Clean Cut infection prevention intervention at random time point &quot;E&quot;</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Clean Cut program</intervention_name>
    <description>Clean Cut, is an adaptive, multimodal surgical infection prevention program that integrates perioperative process improvement and patient outcomes measurement using process mapping, training and improved management practices, and compliance with critical standards of surgical antisepsis</description>
    <arm_group_label>Clean Cut intervention - Cluster 1</arm_group_label>
    <arm_group_label>Clean Cut intervention - Cluster 2</arm_group_label>
    <arm_group_label>Clean Cut intervention - Cluster 3</arm_group_label>
    <arm_group_label>Clean Cut intervention - Cluster 4</arm_group_label>
    <arm_group_label>Clean Cut intervention - Cluster 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any patient undergoing obstetric and gynecologic surgery at any time in one of the&#xD;
             targeted operating theatres is eligible for inclusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  there will be no exclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>women undergoing obstetric or gynecological operations</gender_description>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas G Weiser, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Lifebox Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas G Weiser, MD MPH</last_name>
    <phone>6177945887</phone>
    <email>tweiser@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alert Hospital</name>
      <address>
        <city>Addis Ababa</city>
        <country>Ethiopia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Taye</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ras Desta Hospital</name>
      <address>
        <city>Addis Ababa</city>
        <country>Ethiopia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Taye</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Assela University Hospital</name>
      <address>
        <city>Assela</city>
        <country>Ethiopia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Taye</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dil Chora Referral Hospital</name>
      <address>
        <city>Dire Dawa</city>
        <country>Ethiopia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Taye</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Adare General Hospital</name>
      <address>
        <city>Hawassa</city>
        <country>Ethiopia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Taye</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yirgalem General Hospital</name>
      <address>
        <city>Hawassa</city>
        <country>Ethiopia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Taye</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wolaita Sodo University Hospital</name>
      <address>
        <city>Sodo</city>
        <country>Ethiopia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Taye</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wolkite University Specialized Hospital</name>
      <address>
        <city>Wolkite</city>
        <country>Ethiopia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Taye</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Werabe Comprehensive Specialized Hospital</name>
      <address>
        <city>Worabe</city>
        <country>Ethiopia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Taye</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ambo University Referral Hospital</name>
      <address>
        <city>Ä€mbo</city>
        <country>Ethiopia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Taye</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Ethiopia</country>
  </location_countries>
  <reference>
    <citation>Forrester JA, Koritsanszky L, Parsons BD, Hailu M, Amenu D, Alemu S, Jiru F, Weiser TG. Development of a Surgical Infection Surveillance Program at a Tertiary Hospital in Ethiopia: Lessons Learned from Two Surveillance Strategies. Surg Infect (Larchmt). 2018 Jan;19(1):25-32. doi: 10.1089/sur.2017.136. Epub 2017 Nov 14.</citation>
    <PMID>29135348</PMID>
  </reference>
  <reference>
    <citation>Garland NY, Kheng S, De Leon M, Eap H, Forrester JA, Hay J, Oum P, Sam Ath S, Stock S, Yem S, Lucas G, Weiser TG. Using the WHO Surgical Safety Checklist to Direct Perioperative Quality Improvement at a Surgical Hospital in Cambodia: The Importance of Objective Confirmation of Process Completion. World J Surg. 2017 Dec;41(12):3012-3024. doi: 10.1007/s00268-017-4198-x.</citation>
    <PMID>29038828</PMID>
  </reference>
  <reference>
    <citation>Foster D, Kethman W, Cai LZ, Weiser TG, Forrester JD. Surgical Site Infections after Appendectomy Performed in Low and Middle Human Development-Index Countries: A Systematic Review. Surg Infect (Larchmt). 2018 Apr;19(3):237-244. doi: 10.1089/sur.2017.188. Epub 2017 Oct 23. Review.</citation>
    <PMID>29058569</PMID>
  </reference>
  <reference>
    <citation>Cai LZ, Foster D, Kethman WC, Weiser TG, Forrester JD. Surgical Site Infections after Inguinal Hernia Repairs Performed in Low and Middle Human Development Index Countries: A Systematic Review. Surg Infect (Larchmt). 2018 Jan;19(1):11-20. doi: 10.1089/sur.2017.154. Epub 2017 Oct 19. Review.</citation>
    <PMID>29048997</PMID>
  </reference>
  <reference>
    <citation>Weiser TG, Haynes AB, Molina G, Lipsitz SR, Esquivel MM, Uribe-Leitz T, Fu R, Azad T, Chao TE, Berry WR, Gawande AA. Size and distribution of the global volume of surgery in 2012. Bull World Health Organ. 2016 Mar 1;94(3):201-209F. doi: 10.2471/BLT.15.159293.</citation>
    <PMID>26966331</PMID>
  </reference>
  <reference>
    <citation>Molina G, Weiser TG, Lipsitz SR, Esquivel MM, Uribe-Leitz T, Azad T, Shah N, Semrau K, Berry WR, Gawande AA, Haynes AB. Relationship Between Cesarean Delivery Rate and Maternal and Neonatal Mortality. JAMA. 2015 Dec 1;314(21):2263-70. doi: 10.1001/jama.2015.15553.</citation>
    <PMID>26624825</PMID>
  </reference>
  <reference>
    <citation>Weiser TG, Gawande A. Excess Surgical Mortality: Strategies for Improving Quality of Care. In: Debas HT, Donkor P, Gawande A, Jamison DT, Kruk ME, Mock CN, editors. Essential Surgery: Disease Control Priorities, Third Edition (Volume 1). Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2015 Apr 2. Chapter 16.</citation>
    <PMID>26740999</PMID>
  </reference>
  <reference>
    <citation>Weiser TG, Forrester JD, Forrester JA. Tactics to Prevent Intra-Abdominal Infections in General Surgery. Surg Infect (Larchmt). 2019 Feb/Mar;20(2):139-145. doi: 10.1089/sur.2018.282. Epub 2019 Jan 10. Review.</citation>
    <PMID>30628859</PMID>
  </reference>
  <reference>
    <citation>Rickard J, Beilman G, Forrester J, Sawyer R, Stephen A, Weiser TG, Valenzuela J. Surgical Infections in Low- and Middle-Income Countries: A Global Assessment of the Burden and Management Needs. Surg Infect (Larchmt). 2020 Aug;21(6):478-494. doi: 10.1089/sur.2019.142. Epub 2019 Dec 9.</citation>
    <PMID>31816263</PMID>
  </reference>
  <reference>
    <citation>Mattingly AS, Starr N, Bitew S, Forrester JA, Negussie T, Bereknyei Merrell S, Weiser TG. Qualitative outcomes of Clean Cut: implementation lessons from reducing surgical infections in Ethiopia. BMC Health Serv Res. 2019 Aug 17;19(1):579. doi: 10.1186/s12913-019-4383-8.</citation>
    <PMID>31419972</PMID>
  </reference>
  <reference>
    <citation>Delisle M, Pradarelli JC, Panda N, Koritsanszky L, Sonnay Y, Lipsitz S, Pearse R, Harrison EM, Biccard B, Weiser TG, Haynes AB; Surgical Outcomes Study Groups and GlobalSurg Collaborative. Variation in global uptake of the Surgical Safety Checklist. Br J Surg. 2020 Jan;107(2):e151-e160. doi: 10.1002/bjs.11321.</citation>
    <PMID>31903586</PMID>
  </reference>
  <reference>
    <citation>Starr N, Gebeyehu N, Tesfaye A, Forrester JA, Bekele A, Bitew S, Wayessa E, Weiser TG, Negussie T. Value and Feasibility of Telephone Follow-Up in Ethiopian Surgical Patients. Surg Infect (Larchmt). 2020 Aug;21(6):533-539. doi: 10.1089/sur.2020.054. Epub 2020 Apr 16.</citation>
    <PMID>32301651</PMID>
  </reference>
  <reference>
    <citation>Forrester JA, Starr N, Negussie T, Schaps D, Adem M, Alemu S, Amenu D, Gebeyehu N, Habteyohannes T, Jiru F, Tesfaye A, Wayessa E, Chen R, Trickey A, Bitew S, Bekele A, Weiser TG. Clean Cut (adaptive, multimodal surgical infection prevention programme) for low-resource settings: a prospective quality improvement study. Br J Surg. 2021 Jun 22;108(6):727-734. doi: 10.1002/bjs.11997.</citation>
    <PMID>34157086</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 13, 2021</study_first_submitted>
  <study_first_submitted_qc>March 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Lifebox Foundation</investigator_affiliation>
    <investigator_full_name>Tom Weiser</investigator_full_name>
    <investigator_title>Consulting Medical Officer</investigator_title>
  </responsible_party>
  <keyword>maternal health</keyword>
  <keyword>emergency obstetric and neonatal care</keyword>
  <keyword>surgical infections</keyword>
  <keyword>quality improvement</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data sharing will likely occur at the request of other researchers in accordance with Ethiopian policies governing these data.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>patient data will be available upon completion of the trial</ipd_time_frame>
    <ipd_access_criteria>All reasonable requests</ipd_access_criteria>
    <ipd_url>https://www.lifebox.org/cleancs</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

